/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Barinthus Biotherapeutics (BRNS) generated about n/a in revenue and -$52 million in net income over the trailing twelve months, growing at roughly 32.7% a year. Figures are from SEC filings; this is analysis, not investment advice.
Barinthus Biotherapeutics reported about -$52 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Barinthus Biotherapeutics's revenue has compounded at roughly 32.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside BRNS's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 30 Apr 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 30 Apr 2026. How this is calculated.
Fiscal year ends Dec.